Some GB molecular biomarkers (MB), including mutations in isocitrate dehydrogenase (IDH 1 and 2), epidermal growth factor receptor (EGFR), and p53, among others, have been identified, which allow for predicting tumor progression and, ultimately, helping increase patient survival (Pierscianek et al., 2019; Birkó et al., 2020; Senhaji et al., 2022). The gene discussed is EGFR; the disease is neoplasm.